Hopper Jonathan Mark sold $450K of VCEL
Hopper Jonathan Mark (Chief Medical Officer) sold 10,000 shares of Vericel Corp (VCEL) at $45.00 ($0.45M total) across 2 trades on 2026-06-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the CMO’s open-market sale of 10,000 shares at $45.00/share on 2026-06-26, with holdings after the sale of 75,753 shares.
Market read
Traders may briefly reassess sentiment around VCEL due to insider selling, but the 10b5-1 structure reduces interpretive weight.
What to watch
Insider sales can be mechanically scheduled; traders should check whether there were concurrent buys, option exercises, or other filings around the same period.
Background
This is an SEC Form 4 insider transaction disclosure for Vericel Corp (VCEL) by its Chief Medical Officer.
Ticker impact
Vericel CMO Hopper Jonathan Mark filed an SEC Form 4 selling 10,000 shares at $45.00/share under a 10b5-1 plan.
Low near-term impact; any reaction is likely muted and short-lived.
The filing is a primary-source Form 4, but it is explicitly tied to a pre-arranged 10b5-1 plan and is a single insider sale rather than a new operational or regulatory catalyst.
Market effects
Minimal; insider-sale filings rarely reset sector expectations without accompanying company-specific news.
None.
None.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity/tax planning rather than bearish expectations.
Key entities
- issuerVericel Corp
Company whose insider transaction is disclosed via SEC Form 4.
- insiderHopper Jonathan Mark
Chief Medical Officer who sold shares under a pre-arranged 10b5-1 plan.